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Potential Association of DCBLD2 Polymorphisms with Fall Rates 
of FEV1 by Aspirin Provocation in Korean Asthmatics 
Aspirin exacerbated respiratory disease (AERD) is a clinical syndrome characterized by 
chronic rhinosinusitis with nasal polyposis and aspirin hypersensitivity. The aspirin-induced 
bronchospasm is mediated by mast cell and eosinophilic inflammation. Recently, it has 
been reported that the expression of discoidin, CUB and LCCL domain-containing protein 
2 (DCBLD2) is up-regulated in lung cancers and is regulated by transcription factor AP-2 
alpha (TFAP2A), a component of activator protein-2 (AP-2) that is known to regulate IL-8 
production in human lung fibroblasts and epithelial cells. To investigate the associations 
between AERD and DCBLD2 polymorphisms, 12 common variants were genotyped in 163 
AERD subjects and 429 aspirin tolerant asthma (ATA) controls. Among these variants, seven 
SNPs (rs1371687, rs7615856, rs828621, rs828618, rs828616, rs1062196, and rs8833) 
and one haplotype (DCBLD2-ht1) show associations with susceptibility to AERD. In further 
analysis, this study reveals significant associations between the SNPs or haplotypes and the 
percentage of forced expiratory volume in one second (FEV1) decline following aspirin 
challenge using multiple linear regression analysis. Furthermore, a non-synonymous SNP 
rs16840208 (Asp723Asn) shows a strong association with FEV1 decline in AERD patients. 
Although further studies for the non-synonymous Asp723Asn variation are needed, our 
findings suggest that DCBLD2 could be related to FEV1-related phenotypes in asthmatics.
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INTRODUCTION
Aspirin-exacerbated respiratory disease (AERD), is a clinical 
syndrome with inflammatory responses in both the upper and 
lower respiratory tracts (1). It is characterized by chronic rhino-
sinusitis with nasal polyposis which is followed by asthma and 
hypersensitivity to aspirin (2). Aspirin-induced bronchospasm 
in asthma patients are mediated by mast cell and eosinophilic 
inflammation which is already ongoing before the first aspirin 
ingestion (2, 3). The mechanisms for pathogenesis of AERD are 
not completely explained, however, it has been suggested that 
over-production of cysteinyl leukotriene (CysLT) and its recep-
tor on inflammatory cells occurs in the respiratory tract of AERD 
patients (4).
  The transmembrane protein encoded by discoidin, CUB and 
LCCL domain-containing protein 2 (DCBLD2) gene, also abbre-
viated as CLCP1 or ESDN, is regarded as a contributor for regu-
lation of cell proliferation. Our previous genome-wide and fol-
low-up studies showed nominal associations between DCBLD2 
polymorphisms and AERD (5). Despite little information on the 
function of DCBLD2, this gene has also been elucidated to be 
up-regulated in the development and metastasis of lung can-
cers (6). In addition, the transcription factor TFAP2A induces 
an inhibitory effect on DCBLD2 transcription (7). The TFAP2A, 
an important transcription factor, is a component of activator 
protein-2 (AP-2) that regulates IL-8 expression in human lung 
fibroblasts and epithelial cells (8). On the other hand, previous 
studies have also proposed that the up-regulation of DCBLD2 344   http://jkms.org
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could be involved in pathways related to immune and injury-
mediated remodeling (9, 10). In addition, neuropilin-1, whose 
domains are structurally similar with DCBLD2 domain proteins 
and has been identified as an isoform of a specific vascular en-
dothelial growth factor receptor in human airway epithelial cells, 
showed a higher expression in patients who have chronic rhi-
nosinusitis and/or nasal polyposis (9, 11). 
  Based on the possible relations of DCBLD2 to airway remod-
eling, we investigate further the associations of DCBLD2 single 
nucleotide polymorphisms (SNPs) with the fall rates of forced 
expiratory volume by aspirin provocation as well as AERD de-
velopment under various genetic models.
 
MATERIALS AND METHODS
Study subjects
Asthmatic subjects were recruited from the Asthma Genome 
Research Center comprising hospitals of Soonchunhyang Uni-
versity in Seoul and Bucheon, Chungnam National University 
and Chungbuk National University in Korea. Patients met the 
definition of asthma based on the Global Initiative for Asthma 
guidelines 2010 (http://www.ginasthma.org/guidelines-gina-
report-global-strategy-for-asthma.html). All subjects had a his-
tory of dyspnea and wheezing during the past year plus one of 
the following: 1) > 15% increase in forced expiratory volume in 
one second (FEV1) or  > 12% increase plus 200 mL following in-
halation of a short-acting bronchodilator, 2)  < 10 mg/mL PC20 
methacholine, or 3)  > 20% increase in FEV1 following 2 weeks 
of treatment with inhaled steroids and long-acting bronchodi-
lators. Twenty-four common inhalant allergens (e.g., dust mites, 
cat fur, dog fur, cockroaches, grasses, trees, ragweed pollen; Ben-
card Co. Ltd., Brentford, UK) were used in a skin-prick test. Total 
IgE was measured by the CAP system (Pharmacia Diagnostics, 
Uppsala, Sweden). Atopy was defined as a wheal reaction equal 
to or greater than histamine or 3 mm in diameter. 
  The oral aspirin provocation test was performed with slight 
modifications in increasing doses of aspirin (12), following the 
guideline of EAACI/GA2LEN (13). Briefly, the patient having 
history of aspirin hypersensitivity was given 30 mg and those 
having no history started 100 mg of aspirin orally. Symptoms, 
external signs (urticaria and angioedema), blood pressure and 
FEV1 were documented every 30 min for a period of 2 hr. In the 
absence of any symptoms or signs suggestive of adverse reac-
tion after 2 hr, 60 mg or 100 mg of aspirin was administered and 
the same measurements were repeated every 1 hr, with doses 
of 450 mg until the patient developed a reaction. If no reaction 
occurred 5 hr after the final dose, the test was deemed negative. 
Changes in the FEV1 were followed for 5 hr after the final aspi-
rin dose. Aspirin-induced bronchospasm, reflected by the rate 
(%) of decline in FEV1, was calculated as the pre challenge FEV1 
minus the post challenge FEV1 divided by the pre-challenge FEV1. 
Subjects were categorized into two groups based on OAC reac-
tions: ≥ 20% decrease in FEV1 or a 15%-19% decrease in FEV1 
with naso-ocular reactions as AERD patients group, whereas 
a < 15% decrease in FEV1 without naso-ocular reactions as ATA 
controls group. 
 
SNP selection and genotyping
We selected common SNPs based on the frequencies in Asian 
population from the International HapMap Project database 
(http://hapmap.ncbi.nlm.gov/index.html.en). The selected 12 
SNPs were genotyped in a total of 592 asthmatic subjects com-
posed of 163 AERD and 429 ATA subjects. Genotyping was car-
ried out using TaqMan assay in the ABI prism 7900HT sequence 
detection system (Applied Biosystems, Carlsbad, California, USA) 
with the assessment of data quality by duplicate DNAs (n = 10). 
Genotype data were obtained using the ABI-PRISM sequence 
detection system (SDS) software version 2.3. SNPs that did not 
match the following standards were excluded from the study: 1) 
a minimum call rate of 95%; 2) no duplicate error; and 3) P val-
ues of Hardy-Weinberg Equilibrium more than 0.05. All the 12 
SNPs of DCBLD2 were successfully genotyped.
Statistics
The association of SNPs and haplotypes of DCBLD2 with AERD 
was carried out with logistic analyses controlling for age, sex, 
smoking status, atopy and body mass index (BMI) as covariates 
using the Statistical Analysis System (SAS). The FEV1 change in-
duced by aspirin provocation which was considered as a contin-
uous variable was subjected to a simple linear regression analy-
sis, and the differences in the values among the genotypes or 
haplotypes were examined using a linear regression model that 
controlled for age, sex, atopy and smoking status as covariates. 
For linkage disequilibrium (LD), we examined Lewontin’s D´ 
(|D´|) and the LD coefficient r
2 between all pairs of biallelic loci 
using the Haploview v4.1 software downloaded from the Broad 
Institute (http://www.broadinstitute.org/mpg/haploview) (14). 
Haplotypes were first estimated using PHASE software (15), and 
then computed by logistic analyses using SAS.  
Ethics statement
The institutional review board approved the protocol (SCHBC_
IRB_05_02), and all subjects provided informed consent. 
RESULTS
Characteristics of study subjects
The clinical profiles of the study subjects are summarized in  
Table 1. All of the subjects were asthma patients and were di-
vided into two groups, AERD patients and ATA control groups, 
according to degree of aspirin sensitivity. Overall, a decrease in 
FEV1 of -15% to 68% induced by aspirin provocation was ob-Park T-J, et al.  •  DCBLD2 and FEV1 Decline
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served. The percentage of decrease in FEV1 by aspirin provoca-
tion in AERD patients (24.6%) were significantly higher com-
pared to ATA controls (3.5%; P < 0.001). The values of predicted 
FEV1 %, PC20 methacholine and body mass index in AERD pa-
tients were significantly lower than those of ATA controls (P =  
0.009, 0.02 and 0. 001, respectively). In addition, the mean age 
of a first medical examination in AERD was significantly lower 
than ATA (P = 0.001). Percentage of smoking status in AERD 
patients was also lower compared to ATA controls (P = 0.02).
Genotyping and haplotypes of DCBLD2 polymorphisms
We selected 12 common polymorphisms of DCBLD2, six in exon 
regions and six in introns, based on the frequencies on Asian 
population from the International HapMap Project (Table 2, 
Fig. 1). The minor allele frequencies (MAFs) of these 12 SNPs in 
the Korean asthmatics (n = 592) are shown in Table 2. The gen-
otype distributions of all loci are in Hardy-Weinberg equilibrium 
(Table 2). The linkage disequilibrium coefficients (|D´|) among 
the SNPs were calculated for all of the study subjects (Fig. 1). 
Complete LDs were observed between two SNPs; rs7615856 
and rs828621 (r
2 = 1). Twelve haplotypes were constructed and 
five of them with frequencies over 0.05 (DCBLD-ht1 to DCBLD-
ht5) were included in the association analysis (Fig. 1).
Associations of DCBLD2 polymorphisms with FEV1 
decline and AERD development
Initially, this study investigated the associations between geno-
types or haplotypes and the percentage of FEV1 decline following 
aspirin challenge using multiple linear regression analysis (Table 
3). Interestingly, nine SNPs (rs2439224, rs1371687, rs7615856, 
rs828621, rs828618, rs828616, rs16840208, rs17270986 and rs8833) 
were significantly associated with the percentage FEV1 decline 
induced by aspirin challenge in the asthmatics (P < 0.05, Table 
3). Furthermore, among the significantly associated SNPs, a 
non-synonymous SNP rs16840208 (D723N or Asp723Asn) was 
found to induce a strong genetic effect (P = 0.02 under co-dom-
inant; P = 0.009 in dominant model). In the haplotype analysis, 
DCBLD2-ht1 and DCBLD2-ht4 were also associated with the 
Table 1. Clinical profiles of study subjects
Clinical profiles AERD ATA P value
Number of subjects 163 429
Age of first medical examination (mean [range]) 43.13 (17.22-72.73) 47.30 (15.40-77.88) 0.001
Body mass index (kg/m
2) 23.39 ± 3.25 24.58 ± 3.39 0.001
Fall rate of FEV1 (%)   24.63 ± 16.11   3.54 ± 4.85 < 0.001
Blood eosinophil (%)   5.96 ± 5.21   6.03 ± 5.92 0.88
FEV1 (% predicted)   87.58 ± 16.94   91.66 ± 16.87 0.009 
PC20 methacholine (mg/mL)   5.02 ± 7.83   6.91 ± 8.90 0.02
Total IgE (IU/mL)   348.60 ± 596.44   361.00 ± 607.56 0.83
Sex (male/female) 59/104 147/282 0.66
Current smoker (%) 21.47 30.07 0.02
Positive rate of skin test (%) 52.76 57.81 0.27
Clinical profile of AERD was compared to ATA controls. AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.
Table 2. Single nucleotide polymorphisms and minor allele frequencies of human DCBLD2 in Korean subjects
SNP/Haplotype Allele Position Amino acid change HWE* MAF
rs2439224 T > C Intron1 0.482  0.158 
rs1371687 C > T Intron1 0.800  0.316 
rs9838238 T > C Exon2 I144M 0.459  0.029 
rs17278047 G > C Intron2 0.102  0.064 
rs7615856 T > C Intron2 0.962  0.288 
rs828621 A > T Intron4 0.852  0.288 
rs828618 G > A Intron4 0.440  0.428 
rs828616 A > G Exon6 I262I 0.892  0.318 
rs16840208 C > T Exon16 D723N 0.107  0.055 
rs17270986 A > G 3’UTR 0.955  0.156 
rs1062196 A > G 3’UTR 0.952  0.193 
rs8833 T > C 3’UTR 0.939  0.284 
DCBLD2-ht1 0.482  0.427 
DCBLD2-ht2 0.581  0.254 
DCBLD2-ht3 0.554  0.101 
DCBLD2-ht4 0.107  0.055 
DCBLD2-ht5 0.893  0.059 
*P values of deviation from Hardy-Weinberg Equilibrium (HWE) in Korean population. MAF, minor allele frequency. 346   http://jkms.org
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Fig. 1. Gene maps and haplotypes of DCBLD2. (A) Polymorphisms of DCBLD2 investigated in this study. Coding exons are marked by shaded blocks; 5´- and 3´-untranslated 
region (UTR) by white blocks. Two SNPs (rs7615856 and rs828621) are in complete LD (r
2 = 1). (B) Haplotypes of DCBLD2 in the Korean population. Only those with frequen-
cies over 0.05 are analyzed for associations. (C) LD blocks and correlation coefficients among DCBLD2 polymorphisms. 
Table 3. Association of SNPs and haplotypes of DCBLD2 with FEV1 decline by aspirin provocation in asthmatics
SNP/Haplotype Allele
Genotype P value
C/C C/R R/R Co-dominant Dominant Recessive
rs2439224
rs1371687
rs9838238
rs17278047
rs7615856
rs828621
rs828618
rs828616
rs16840208
rs17270986
rs1062196
rs8833
T > C
C > T
T > C
G > C
T > C
A > T
G > A
A > G
C > T
A > G
A > G
T > C
423 (10.03 ± 14.10)
281 (10.15 ± 14.30)
558 (9.34 ± 13.36)
522 (9.47 ± 13.51)
304 (10.03 ± 14.09)
304 (10.03 ± 14.09)
190 (7.02 ± 9.20)
279 (10.25 ± 14.30)
531 (9.71 ± 13.54)
423 (10.03 ± 14.10)
386 (9.75 ± 13.45)
305 (10.17 ± 14.02)
152 (7.30 ± 10.88)
251 (9.17 ± 12.89)
34 (7.52 ± 10.75)
65 (7.56 ± 10.94)
239 (9.04 ± 12.91)
238 (9.10 ± 12.91)
294 (10.06 ± 14.48)
253 (9.07 ± 12.89)
57 (4.91 ± 9.31)
155 (7.22 ± 10.80)
184 (8.53 ± 13.31)
240 (8.82 ± 12.90)
17 (6.71 ± 5.62)
60 (5.23 ± 7.48)
-
5 (6.38 ± 7.34)
49 (5.21 ± 7.14)
50 (5.05 ± 7.16)
108 (10.87 ± 15.12)
60 (5.23 ± 7.48)
4 (7.68 ± 4.71)
14 (7.41 ± 5.86)
21 (6.24 ± 6.07)
47 (5.29 ± 7.74)
0.02 
0.03 
0.59 
0.39 
0.04 
0.04 
0.02 
0.02 
0.02 
0.03 
0.15 
0.04 
0.02 
0.16 
0.59 
0.40 
0.17 
0.17 
0.01 
0.12 
  0.009 
0.02 
0.19 
0.12 
0.45 
0.02 
-
0.69 
0.03 
0.02 
0.23 
0.02 
0.80 
0.66 
0.33 
0.05 
DCBLD2-ht1
DCBLD2-ht2
DCBLD2-ht3
DCBLD2-ht4
DCBLD2-ht5
-/-
191 (6.97 ± 9.20)
332 (9.34 ± 13.64)
479 (9.45 ± 13.72)
531 (9.71 ± 13.54)
525 (9.43 ± 13.49)
+/-
293 (10.11 ± 14.48)
219 (9.23 ± 13.25)
108 (8.29 ± 11.06)
57 (4.91 ± 9.31)
65 (7.76 ± 11.03)
+/+
108 (10.87 ± 15.12)
41 (8.33 ± 9.16)
5 (9.08 ± 6.22)
4 (7.68 ± 4.71)
2 (4.45 ± 1.63)
0.02 
0.81 
0.46 
0.02 
0.47 
0.01 
0.90 
0.44 
  0.009 
0.51 
0.23 
0.74 
0.95 
0.80 
0.64 
Genotype distribution of each SNP is presented as the number of subjects (percentage of FEV1 decline by aspirin provocation, mean ± SE). P values for linear regression analy-
sis controlling age, sex, smoking status and atopy as covariates. C/C, Major homozygote; C/R, Heterozygote; R/R, Minor homozygote.
A
Map of DCBLD2 (discoidin, CUB and LCCL domain containing 2) on chromosome 3q12.1;3 (106 Kb)
B
Haplotypes in DCBLD2
C
LDs among DCBLD2 polymorphismsPark T-J, et al.  •  DCBLD2 and FEV1 Decline
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percentage FEV1 decline induced by aspirin challenge in the 
asthmatics (P = 0.009 for DCBLD2-ht4 under dominant model 
to P = 0.02 for DCBLD2-ht1 and DCBLD2-ht4 under co-domi-
nant, Table 3).
  Furthermore, results from regression analysis comparing 
AERD and ATA groups revealed that nine SNPs (P = 0.001 for 
rs828618 under dominant model to P = 0.05 for rs2439224, 
rs828618, rs17270986 under co-dominant) and two haplotypes 
(P = 0.001 for DCBLD2-ht1 under dominant model to P = 0.05 
for DCBLD2-ht1 under dominant; P = 0.03 for DCBLD2-ht2 
under recessive) were significantly associated with the percent-
age FEV1 decline induced by aspirin challenge in AERD patients 
(Supplementary Table 1). In contrast, findings from regression 
analysis of ATA group showed no significant association between 
DCBLD2 SNPs and FEV1 decline induced by aspirin provoca-
tion, except for DCBLD2-ht1 haplotype (P = 0.02 in recessive 
model, Supplementary Table 1). 
  In further association analysis between DCBLD2 SNPs/hap-
lotypes and the risk of AERD using multiple logistic models, two 
SNPs (rs828618 and rs828616; P = 0.05 and P = 0.04, respective-
ly) and one haplotype (DCBLD2-ht1; P = 0.05) showed nominal 
signals with the risk of AERD (Table 4).
DISCUSSION
To our knowledge, this study is the first to investigate the asso-
ciation between DCBLD2 and AERD. In this study, data from 
logistic and linear regression analyses showed significant asso-
ciations of DCBLD2 polymorphisms with FEV1 decline by aspi-
rin provocation (P = 0.009 for rs16840208 under dominant model 
to P = 0.04 for rs7615856, rs828621 and rs8833 under co-domi-
nant, Table 3) and nominal signals to AERD development (P =  
0.04 for rs828616 to P = 0.05 for rs828618 under co-dominant 
model, Table 4). Furthermore, the strength of association with 
the fall rate of FEV1 by aspirin provocation was increased in the 
AERD subgroup (P = 0.001 for rs828618 under dominant model 
to P = 0.05 for rs2439224, rs828618, rs17270986 under co-domi-
nant, Supplementary Table 1) compared to ATA (P > 0.05), sug-
gesting that genetic variations of DCBLD2 may affect decline of 
FEV1 by aspirin provocation in AERD patients.
  Recently, a significant up-regulation of DCBLD2, previously 
identified as CLCP1, has been elucidated in the metastasis of 
lung cancer cell line (6), suggesting that DCBLD2 potentially 
plays a role in lung-related functions. In addition, DCBLD2, also 
known as ESDN, is a key factor in the modulation of vascular 
smooth muscle cell (VSMC) growth and regulation of VSMC 
proliferation processes that are involved in vascular remodel-
ing. DCBLD2 is up-regulated in remodeling arteries, and its 
down-regulation by RNA interference (RNAi) has been found 
to significantly enhance VSMC DNA synthesis and migration 
through induction of platelet-derived growth factor (PDGF), a 
prototypic growth factor for VSMCs (10, 16). 
  The transcription factor TFAP2A, a member of the AP-2 fam-
ily, plays an important role in regulation of DCBLD2 transcrip-
tion. It has been shown that TFAP2A binding to DCBLD2 pro-
moter region induces a decrease in promoter activity measured 
by luciferase assay in this gene. Conversely, mutations in TFAP2A 
binding site in DCBLD2 promoter lead to the increase in tran-
Table 4. Analyses of association of DCBLD2 polymorphisms with risk of AERD
SNP/Haplotype Allele Position
MAF Co-dominant Dominant Recessive
AERD  
(n = 163)
ATA  
(n = 429)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs2439224 T > C Intron1 0.129 0.170 0.74 (0.51-1.07) 0.11  0.71 (0.47-1.09) 0.11  0.61 (0.17-2.20) 0.45 
rs1371687 C > T Intron1 0.267 0.334 0.75 (0.56-1.00) 0.05  0.72 (0.50-1.04) 0.08  0.61 (0.31-1.23) 0.17 
rs9838238 T > C Exon2 0.025 0.030 0.83 (0.36-1.91) 0.66  0.83 (0.36-1.91) 0.66  - -
rs17278047 G > C Intron2 0.052 0.068 0.89 (0.51-1.55) 0.68  0.88 (0.48-1.62) 0.69  0.81 (0.08-7.87) 0.86 
rs7615856 T > C Intron2 0.242 0.304 0.75 (0.56-1.02) 0.06  0.73 (0.50-1.05) 0.09  0.62 (0.29-1.32) 0.21 
rs828621 A > T Intron4 0.242 0.305 0.75 (0.56-1.01) 0.06  0.73 (0.50-1.05) 0.09  0.60 (0.28-1.29) 0.19 
rs828618 G > A Intron4 0.482 0.409 1.31 (1.00-1.71) 0.05  1.32 (0.88-1.99) 0.18  1.57 (0.99-2.48) 0.05 
rs828616 A > G Exon6 0.267 0.337 0.74 (0.55-0.99) 0.04  0.71 (0.49-1.02) 0.07  0.61 (0.31-1.23) 0.17 
rs16840208 C > T Exon16 0.040 0.062 0.66 (0.35-1.23) 0.19  0.61 (0.31-1.20) 0.15  0.99 (0.10-9.79) 0.99 
rs17270986 A > G Exon16 0.129 0.167 0.75 (0.51-1.09) 0.13  0.71 (0.47-1.09) 0.11  0.79 (0.21-2.93) 0.73 
rs1062196 A > G Exon16 0.163 0.204 0.76 (0.54-1.08) 0.13  0.68 (0.46-1.02) 0.06  1.16 (0.43-3.10) 0.77 
rs8833 T > C Exon16 0.236 0.302 0.75 (0.56-1.02) 0.07  0.71 (0.49-1.03) 0.07  0.71 (0.33-1.53) 0.39 
DCBLD2-ht1 0.482 0.408 1.32 (1.01-1.72) 0.05  1.33 (0.89-2.01) 0.17  1.57 (0.99-2.48) 0.05 
DCBLD2-ht2 0.252 0.254 0.99 (0.74-1.34) 0.95  0.95 (0.65-1.37) 0.77  1.17 (0.57-2.40) 0.67 
DCBLD2-ht3 0.089 0.105 0.83 (0.53-1.31) 0.43  0.84 (0.52-1.35) 0.46  0.59 (0.06-5.50) 0.64 
DCBLD2-ht4 0.040 0.062 0.66 (0.35-1.23) 0.19  0.61 (0.31-1.20) 0.15  0.99 (0.10-9.79) 0.99 
DCBLD2-ht5 0.049 0.062 0.92 (0.51-1.67) 0.79  0.95 (0.52-1.74) 0.86  - -
Logistic analyses controlling for age, sex, smoking status, atopy and body mass index (BMI) as covariates are performed using the Statistical Analysis System (SAS). OR (95% 
CI) and P values of co-dominant model are also reported in the supporting information of our previous report (Kim et al. 2010b). MAF, minor allele frequency; OR, odds ratio; CI, 
confidence interval.348   http://jkms.org
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scription activity (7). AP-2 is a regulator for IL-8 production that 
is associated with the destructive pulmonary inflammation and 
the recruitment of neutrophils. Deletion of AP-2 binding site in 
the upstream region of IL-8 promoter significantly decreased 
IL-8 transcription activity (8), suggesting that DCBLD2 might 
be related to the production of interleukins in human pulmo-
nary diseases through interaction with AP-2. This possibility is 
supported by the facts that discodin domain affects immune 
responses in the involvement of interleukins (17, 18).
  Although the functional properties of DCBLD2 in tumor de-
velopment and vascular remodeling have been reported, to date 
no previous study has proposed the functional or genetic effects 
of DCBLD2 on asthma and aspirin-induced hypersensitivity. 
However, neuropilin-1, which is structurally similar to DCBLD2 
(19) has been found to be related to the suppressor function of 
CD4
+CD25
+ T cells in airway inflammation and hyper-respon-
siveness (20). In addition, neuropilin-1 is associated with the 
development of nasal polyposis, one of the symptoms of AERD. 
Distribution of neuropilin-1, as a co-receptor of vascular endo-
thelial growth factor (VEGF), was shown to be 7-fold higher in 
nasal lavage from patients with polyposis than control subjects. 
Moreover, blockade of VEGF, which is suppressed by neuropi-
lin-1, results in increased apoptosis and inhibition of autocrine 
epithelial VGEF production (11). Therefore, with the structural 
similarity to neuropilin-1, there is a possibility DCBLD2 may 
play a similar role in aspirin sensitivity to asthma.
  The bronchoalveolar lavage (BAL) in asthma has been impli-
cated in asparagine levels. The BAL fluid from asthmatic patients 
showed higher level of asparagine (Asn, N) than from normal 
controls (21). Other studies have reported that a polymorphism 
in the human neuropeptide S receptor (NPSR) which produces an 
amino acid substitution from Asn to isoleusine (Ile) (Asn107Ile) 
is associated with susceptibility to asthma. The Asn107Ile poly-
morphism of NPSR was found to be highly expressed in human 
asthmatic airway tissue (22, 23). In the present study, rs16840208 
(Asp723Asn) is significantly associated with FEV1 decline by as-
pirin provocation (P = 0.02 under co-dominant and 0.009 un-
der dominant model), suggesting that the amino acid change 
from aspartic acid (Asp) to asparagine of rs16840208 may be a 
genetic factor affecting the risk of pulmonary diseases includ-
ing asthma.
  Among the SNPs associated with FEV1 decline by aspirin prov-
ocation and/or AERD, 5 SNPs (rs2439224, rs1371687, rs7615856, 
rs828621, and rs828618) were located in intronic region of DCBLD2. 
Despite difficulty in assessing the functions of SNPs that are not 
positioned at the exon and promoter regions, previous studies 
have suggested that intronic SNPs may play important roles in 
gene transcription rate and abnormal splicing events such as 
exon skipping, activation of cryptic splice sites and production 
of alternatively spliced isoforms in human disease phenotypes 
(24, 25). Furthermore, it has also been reported that intronic 
SNPs in solute carrier family 6, member 7 (SLC6A7) (26), solute 
carrier family 6, member 12 (SLC6A12) (27), kinesin family num-
ber 3A (KIF3A) (28), calcium channel, voltage-dependent, gamma 
subunit 6 (CACNG6) (29) and fibrous sheath interacting protein 1 
(FSIP1) (30) are associated with asthma and/or decline in FEV1 
by aspirin challenge.
  In summary, findings from this study provide evidences that 
genetic polymorphisms of DCBLD2 including a non-synony-
mous rs16840208 (Asp723Asn) might induce decline in FEV1 by 
aspirin ingestion in Korean asthma patients. Furthermore, con-
sidering that 5-lipoxygenase, whose pathway is one of the cen-
tral mechanisms to produce CysLTs from arachidonic acid (31), 
plays a role in VSMC that is modulated by DCBLD2 (10, 32), these 
findings suggest that genetic variants of DCBLD2 could provide 
a new strategy for the control of aspirin intolerance. 
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Supplementary Table 1.﻿Association﻿of﻿SNPs﻿and﻿haplotypes﻿of﻿DCBLD2﻿with﻿FEV1﻿decline﻿by﻿aspirin﻿provocation﻿in﻿AERD﻿and﻿in﻿ATA﻿group
SNP/﻿
Haplotype
Allele
Genotype P﻿value
C/C C/R R/R Co-dominant Dominant Recessive
In﻿AERD rs2439224
rs1371687
rs9838238
rs17278047
rs7615856
rs828621
rs828618
rs828616
rs16840208
rs17270986
rs1062196
rs8833
DCBLD2-ht1
DCBLD2-ht2
DCBLD2-ht3
DCBLD2-ht4
DCBLD2-ht5
T > C
C > T
T > C
G > C
T > C
A > T
G > A
A > G
C > T
A > G
A > G
T > C
﻿
﻿
﻿
﻿
﻿
123﻿(25.78 ± 16.67)
87﻿(25.22 ± 16.56)
152﻿(24.90 ± 16.14)
144﻿(24.82 ± 16.59)
93﻿(24.87 ± 16.55)
93﻿(24.87 ± 16.55)
43﻿(17.72 ± 12.43)
87﻿(25.22 ± 16.56)
149﻿(25.15 ± 16.28)
123﻿(25.78 ± 16.67)
115﻿(24.38 ± 15.67)
94﻿(24.99 ± 16.24)
43﻿(17.72 ± 12.43)
91﻿(24.70 ± 17.18)
133﻿(25.17 ± 16.50)
149﻿(25.15 ± 16.28)
144﻿(24.82 ± 16.59)
34﻿(21.51 ± 13.92)
62﻿(25.57 ± 15.96)
8﻿(19.51 ± 15.67)
15﻿(23.21 ± 11.46)
58﻿(25.92 ± 15.81)
58﻿(25.92 ± 15.81)
79﻿(28.51 ± 15.84)
62﻿(25.57 ± 15.96)
10﻿(18.71 ± 12.06)
34﻿(21.51 ± 13.92)
39﻿(27.60 ± 17.26)
57﻿(25.70 ± 16.20)
79﻿(28.51 ± 15.84)
57﻿(26.59 ± 14.04)
26﻿(22.12 ± 14.24)
10﻿(18.71 ± 12.06)
16﻿(22.89 ± 11.14)
3﻿(12.80 ± 5.94)
11﻿(14.66 ± 9.85)
0﻿(.)
﻿﻿﻿1﻿(18)
9﻿(13.81 ± 9.15)
9﻿(13.81 ± 9.15)
38﻿(24.36 ± 17.97)
11﻿(14.66 ± 9.85)
﻿1﻿(6)
3﻿(12.80 ± 5.94)
6﻿(9.88 ± 7.59)
9﻿(14.03 ± 10.90)
38﻿(24.36 ± 17.97)
12﻿(14.72 ± 14.32)
﻿﻿﻿1﻿(17)
﻿1﻿(6)
0﻿(.)
0.05﻿
0.18﻿
0.47﻿
0.63﻿
0.26﻿
0.26﻿
0.05﻿
0.18﻿
0.07﻿
0.05﻿
0.45﻿
0.25﻿
0.05﻿
0.38﻿
0.31﻿
0.07﻿
0.67﻿
0.08﻿
0.55﻿
0.47﻿
0.67﻿
0.71﻿
0.71﻿
﻿﻿0.001﻿
0.55﻿
0.10﻿
0.08﻿
0.94﻿
0.65﻿
﻿﻿0.001
0.99﻿
0.31﻿
0.10﻿
0.67﻿
0.19﻿
0.03 
-
0.73﻿
0.03﻿
0.03﻿
0.95﻿
0.03﻿
0.22﻿
0.19﻿
0.02﻿
0.04﻿
0.95﻿
0.03﻿
0.72﻿
0.22﻿
-
In﻿ATA rs2439224
rs1371687
rs9838238
rs17278047
rs7615856
rs828621
rs828618
rs828616
rs16840208
rs17270986
rs1062196
rs8833
DCBLD2-ht1
DCBLD2-ht2
DCBLD2-ht3
DCBLD2-ht4
DCBLD2-ht5
T > C
C > T
T > C
G > C
T > C
A > T
G > A
A > G
C > T
A > G
A > G
T > C
297﻿(3.59 ± 4.88)
191﻿(3.41 ± 5.16)
403﻿(3.52 ± 4.85)
375﻿(3.63 ± 4.89)
208﻿(3.51 ± 5.15)
208﻿(3.51 ± 5.15)
147﻿(3.89 ± 4.64)
189﻿(3.48 ± 5.13)
379﻿(3.70 ± 4.76)
297﻿(3.59 ± 4.88)
268﻿(3.56 ± 4.97)
208﻿(3.59 ± 5.09)
148﻿(3.85 ± 4.66)
240﻿(3.56 ± 4.79)
343﻿(3.42 ± 4.97)
379﻿(3.70 ± 4.76)
378﻿(3.63 ± 4.88)
118﻿(3.20 ± 4.75)
189﻿(3.79 ± 4.53)
26﻿(3.83 ± 4.87)
50﻿(2.86 ± 4.61)
1﻿81﻿(3.64 ± 4.48)
180﻿(3.68 ± 4.46)
213﻿(3.29 ± 4.88)
191﻿(3.71 ± 4.57)
47﻿(1.98 ± 5.18)
121﻿(3.21 ± 4.71)
145﻿(3.40 ± 4.64)
183﻿(3.56 ± 4.53)
212﻿(3.32 ± 4.87)
160﻿(3.13 ± 5.03)
82﻿(3.90 ± 4.25)
47﻿(1.98 ± 5.18)
49﻿(2.81 ± 4.70)
14﻿(5.40 ± 4.80)
49﻿(3.11 ± 4.85)
0﻿(.)
4﻿(3.48 ± 3.96)
40﻿(3.28 ± 4.96)
41﻿(3.12 ± 5.00)
69﻿(3.58 ± 5.21)
49﻿(3.11 ± 4.85)
3﻿(8.23 ± 5.60)
11﻿(5.94 ± 5.15)
15﻿(4.79 ± 4.92)
38﻿(3.22 ± 5.08)
69﻿(3.58 ± 5.21)
29﻿(5.69 ± 3.81)
4﻿(7.10 ± 5.05)
3﻿(8.23 ± 5.60)
2﻿(4.45 ± 1.63)
0.86﻿
0.94﻿
0.77﻿
0.37﻿
0.98﻿
0.92﻿
0.51﻿
0.89﻿
0.23﻿
0.85﻿
0.75﻿
0.77﻿
0.56﻿
0.39﻿
0.23﻿
0.23﻿
0.40﻿
0.75﻿
0.55﻿
0.77﻿
0.33﻿
0.79﻿
0.79﻿
0.27﻿
0.75﻿
0.08﻿
0.75﻿
1.00﻿
0.95﻿
0.32﻿
0.89﻿
0.34﻿
0.08﻿
0.33﻿
0.17﻿
0.44﻿
-
0.91﻿
0.62﻿
0.50﻿
0.84﻿
0.44﻿
0.10﻿
0.11﻿
0.34﻿
0.57﻿
0.84﻿
0.02﻿
0.14﻿
0.10﻿
0.74﻿
Genotype﻿distribution﻿of﻿each﻿SNP﻿is﻿presented﻿as﻿the﻿number﻿of﻿subjects﻿(percentage﻿of﻿FEV1﻿decline﻿by﻿aspirin﻿provocation,﻿mean ± SE).﻿P﻿values﻿for﻿linear﻿regression﻿analy-
sis﻿controlling﻿age,﻿sex,﻿smoking﻿status﻿and﻿atopy﻿as﻿covariates.﻿C/C,﻿Major﻿allele﻿homozygote;﻿C/R,﻿Heterozygote;﻿R/R,﻿Minor﻿allele﻿homozygote.